Algunos riesgos an no han podido descartarse por falta de estudios al respecto
What they found: No serious adverse events triggered by AOD-9604 The most frequent side effects: headache (~5 %), occasional fatigue, at the same frequency as placebo No changes in IGF-1 levels, glycemia, blood pressure, heart rate No signals of cardiovascular, hepatic or renal toxicity Safety profile comparable to placebo Why it matters: From a safety perspective, AOD-9604 is one of the safest peptides in the clinical registry
found that patients with bacteremic Pneumococcal pneumonia had significantly greater blood IL-8 levels on admission than patients with Chlamydia pneumonia , Legionella pneumonia , or influenza A virus infection [111]
Acta 1859 , 15581572 (2017)
Novo's oral Wegovy has an early lead, while Lilly's newly approved oral GLP-1, Foundayo, had a slower early prescription ramp